Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 09, 2021

SELL
$31.56 - $42.16 $86,190 - $115,138
-2,731 Closed
0 $0
Q3 2020

Nov 02, 2020

BUY
$23.19 - $41.61 $63,331 - $113,636
2,731 New
2,731 $92,000
Q2 2020

Aug 11, 2020

SELL
$14.82 - $29.92 $10,210 - $20,614
-689 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$11.67 - $27.23 $2,695 - $6,290
231 Added 50.44%
689 $11,000
Q4 2019

Feb 13, 2020

BUY
$16.92 - $28.96 $203 - $347
12 Added 2.69%
458 $11,000
Q3 2019

Oct 17, 2019

SELL
$20.0 - $31.88 $31,600 - $50,370
-1,580 Reduced 77.99%
446 $9,000
Q2 2019

Aug 05, 2019

BUY
$30.67 - $37.86 $55,206 - $68,148
1,800 Added 796.46%
2,026 $65,000
Q1 2019

Apr 16, 2019

BUY
$22.22 - $32.21 $777 - $1,127
35 Added 18.32%
226 $7,000
Q4 2018

Jan 17, 2019

BUY
$20.9 - $32.57 $3,991 - $6,220
191 New
191 $5,000

Others Institutions Holding ALBO

About ALBIREO PHARMA, INC.


  • Ticker ALBO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,612,500
  • Description
  • Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...
More about ALBO
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.